Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.62 |
| ▸ | NPC1 | O15118 | 8/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14580974 | 0.89 | RAB9A (0.51) | RAB9ANPC1GAAKMT2AHDAC3 | |
| SCHEMBL2037095 | 0.87 | NPC1 (0.57) | RAB9ANPC1KMT2AHDAC3NCOR2 | |
| SCHEMBL27562115 | 0.85 | RAB9A (0.47) | RAB9ANPC1GAAKMT2AHDAC3 | |
| SCHEMBL13314114 | 0.85 | NPC1 (0.59) | RAB9ANPC1HDAC3NCOR2ALDH1A1 | |
| SCHEMBL7970712 | 0.85 | NPC1 (0.62) | RAB9ANPC1HDAC3NCOR2EGFR | |
| SCHEMBL13607002 | 0.85 | NPC1 (0.62) | RAB9ANPC1HDAC3NCOR2ALDH1A1 | |
| SCHEMBL7424713 | 0.85 | NPC1 (0.62) | RAB9ANPC1KMT2AHDAC3NCOR2 | |
| SCHEMBL9800175 | 0.85 | NPC1 (0.62) | RAB9ANPC1HDAC3NCOR2ALDH1A1 | |
| SCHEMBL7981993 | 0.85 | HDAC3 (0.64) | RAB9ANPC1HDAC3NCOR2EGFR | |
| SCHEMBL27812554 | 0.84 | HDAC3 (0.60) | RAB9ANPC1KMT2AHDAC3NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200247794-A1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIVERSITY TECHNOLOGY (ZA) | 2020-08-06 | — | — | US | claimed |
| EP-3365819-A2 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | Mangosuthu University Of Technology (ZA) | 2018-08-29 | — | — | EP | claimed |
| WO-2017070719-A2 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIVERSITY OF TECHNOLOGY (ZA) | 2017-04-27 | — | — | WO | claimed |
| EP-1299377-A2 | SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-04-09 | — | — | EP | claimed |
| WO-2002000641-A2 | SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-01-03 | — | — | WO | claimed |
| EP-3365330-B1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIV OF TECHNOLOGY (ZA) | 2023-06-07 | — | — | EP | disclosed |
| EP-3365819-B1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIV OF TECHNOLOGY (ZA) | 2023-06-07 | — | — | EP | disclosed |
| US-11548860-B2 | Pharmacophores, compounds and methods having application in the treatment of cancer through inhibition of CYP17A1 and CYP19A1 | MANGOSUTHU UNIVERSITY OF TECHNOLOGY (ZA) | 2023-01-10 | — | — | US | disclosed |
| WO-2022087317-A1 | THIOHYDROXYPYRIDINE CHELATES | LUMIPHORE, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20200247764-A1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIVERSITY TECHNOLOGY (ZA) | 2020-08-06 | — | — | US | disclosed |
| US-20200247794-A1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | MANGOSUTHU UNIVERSITY TECHNOLOGY (ZA) | 2020-08-06 | — | — | US | disclosed |
| WO-2019173639-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. (US) | 2019-09-12 | — | — | WO | disclosed |
| EP-0961766-A1 | PHENOXYACETIC ACID DERIVATIVES AND THEIR USE AS HERBICIDES | Rhone Poulenc Agro (FR) | 1999-12-08 | — | — | EP | disclosed |
| US-5990161-A | PESTICIDES, FUNGICIDES AND INSECTICIDES FOR KILLING ANTHROPODS; PLANT PROTECTION; CROPS; CONTROLLING | RHONE-POULENC AGROCHIMIE (FR) | 1999-11-23 | — | — | US | disclosed |
| US-5919825-A | PLANT SAFENING AGENT; INSECTICIDES; FUNGICIDES | RHONE-POULENC AGROCHIMIE (FR) | 1999-07-06 | — | — | US | disclosed |
| WO-1998034898-A1 | PHENOXYACETIC ACID DERIVATIVES AND THEIR USE AS HERBICIDES | RHONE-POULENC AGRO (FR) | 1998-08-13 | — | — | WO | disclosed |
| CN-1187810-A | New hydroximic acid derivatives | RHONE POULENC AGROCHIMIE (FR) | 1998-07-15 | — | — | CN | disclosed |
| EP-0821667-A1 | NEW HYDROXIMIC ACID DERIVATIVES | RHONE-POULENC AGROCHIMIE (FR) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996033164-A1 | NEW HYDROXIMIC ACID DERIVATIVES | RHONE-POULENC AGROCHIMIE (FR) | 1996-10-24 | — | — | WO | disclosed |
| EP-0731797-A1 | PARAMAGNETIC CHELATES FOR NUCLEAR MAGNETIC RESONANCE DIAGNOSIS | BRACCO S.p.A. (IT) | 1996-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247794-A1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | CYP19A1, CYP26A1, CYP21A2 | RAB9A 3461/4885NPC1 918/4885GAA 3272/4885 |
| US-20200247764-A1 | PHARMACOPHORES, COMPOUNDS AND METHODS HAVING APPLICATION IN THE TREATMENT OF CANCER THROUGH INHIBITION OF CYP17A1 AND CYP19A1 | CYP19A1, CYP26A1, CYP21A2 | RAB9A 3635/4885NPC1 619/4885GAA 3642/4885 |
| US-11548860-B2 | Pharmacophores, compounds and methods having application in the treatment of cancer through inhibition of CYP17A1 and CYP19A1 | CYP19A1, CYP26A1, CYP21A2 | RAB9A 3635/4885NPC1 619/4885GAA 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.